AuroSource joins India’s $1.5bn CRAMS sector

By Staff reporter

- Last updated on GMT

Related tags: Pharmacology

Indian generic drugmaker Aurobindo Pharma officially launched its CRAMS unit AuroSource last week, also unveiling plans for an R&D facility in Pashamylaram near Hyderabad, India.

The new division, which will provide medicinal chemistry and active pharmaceutical ingredient (API) development services at six facilities across India, is intended to capture a share of the country’s $1.5bn (€1.1bn) contract research and manufacturing services (CRAMS) sector.

AuroSource suggested that: “This is a critical time to enter the [CRAMS] market,” ​and added that Big Pharma’s adoption of outsourcing strategies as a key driver for development of the new business.

The firm also said that: “Impending reforms in the US healthcare market have exposed a need for contract manufacturing services.​”

Generics licensing deal

In other news, Aurobindo is set to sign several new generics licensing deals with several major global drugmakers according to Ramprasad Reddy, Chairman of Aurobindo.

He told expressbuzz​ that the firm, which recently signed a generics licensing agreement with US drug giant Pfizer, “anticipate to close deals with 2-3 multinationals over the next few months​.”

Aurobindo will also join the $8bn a year oral contraceptives sector in the next three years, initially targeting the US that, the firm said, accounts for some 45 per cent of the global market.

Reddy explained to the Financial Express​ that the company’s manufacturing plant for oral contraceptives is expected to be ready in the next five to six months.

We hope to launch the first generic oral contraceptive product during the first quarter of FY12 in the regulated markets,​’’ he added.

Related news

Show more

Related products

show more

Facilities: Riverview, MI USA

Facilities: Riverview, MI USA

Piramal Pharma Solutions | 26-Jul-2021 | Insight Guide

The Piramal Pharma Solutions facility in Riverview, MI, USA can support your Drug Substance (API) needs. The site has extensive experience in safely delivering...

Facilities: Morpeth, UK

Facilities: Morpeth, UK

Piramal Pharma Solutions | 26-Jul-2021 | Insight Guide

The Piramal Pharma Solutions facility in Morpeth, UK offers Active Pharmaceutical Ingredients (APIs) and oral solid drug product development, clinical...

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Related suppliers

Follow us


View more